Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)

D. Elias; H. Vever; A. V. Lænkholm; M. F. Gjerstorff; C. W. Yde; A. E. Lykkesfeldt; H. J. Ditzel

doi:10.1038/s41388-018-0495-6

Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)

D. Elias^*, H. Vever, A. V. Lænkholm, M. F. Gjerstorff, C. W. Yde, A. E. Lykkesfeldt, H. J. Ditzel

^*Corresponding author for this work

Research output: Contribution to journal › Comment/debate › Research › peer-review

115 Downloads (Pure)

Abstract

Since the online publication of the above article, the authors have noted errors in subfigures 1c and 3b. Therefore, new images of the original immmunocytochemistry stainings have been obtained for Fig. 1c, and the Western blots for siRNA-mediated FYN knockdown in Fig. 3b were repeated. The amended versions of Figs. 1c and 3b are now provided.

Original language	English
Journal	Oncogene
Volume	37
Issue number	41
Pages (from-to)	5585–5586
ISSN	0950-9232
DOIs	https://doi.org/10.1038/s41388-018-0495-6
Publication status	Published - Oct 2018

Documents & Links

10.1038/s41388-018-0495-6Licence: CC BY

Correction to Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapyFinal published version, 852 KBLicence: CC BY

Fingerprint

Dive into the research topics of 'Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)'. Together they form a unique fingerprint.

1 Comment/debate

Correction: VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway (Oncogene, (2018), 37, 41, (5585-5586), 10.1038/s41388-018-0495-6)
Elias, D., Vever, H., Lænkholm, A. V., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E. & Ditzel, H. J., Mar 2020, In: Oncogene. 39, 10, p. 2229-2230
Research output: Contribution to journal › Comment/debate › Research › peer-review

Open Access
File
26 Downloads (Pure)

Cite this

Elias, D., Vever, H., Lænkholm, A. V., Gjerstorff, M. F., Yde, C. W., Lykkesfeldt, A. E., & Ditzel, H. J. (2018). Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138). Oncogene, 37(41), 5585–5586 . https://doi.org/10.1038/s41388-018-0495-6

@article{d3f4f19579454447862fabc94e0e931c,

title = "Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)",

abstract = "Since the online publication of the above article, the authors have noted errors in subfigures 1c and 3b. Therefore, new images of the original immmunocytochemistry stainings have been obtained for Fig. 1c, and the Western blots for siRNA-mediated FYN knockdown in Fig. 3b were repeated. The amended versions of Figs. 1c and 3b are now provided.",

author = "D. Elias and H. Vever and L{\ae}nkholm, {A. V.} and Gjerstorff, {M. F.} and Yde, {C. W.} and Lykkesfeldt, {A. E.} and Ditzel, {H. J.}",

year = "2018",

month = oct,

doi = "10.1038/s41388-018-0495-6",

language = "English",

volume = "37",

pages = "5585–5586 ",

journal = "Oncogene",

issn = "0950-9232",

publisher = "Nature Publishing Group",

number = "41",

}

Elias, D, Vever, H, Lænkholm, AV, Gjerstorff, MF, Yde, CW, Lykkesfeldt, AE & Ditzel, HJ 2018, 'Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)', Oncogene, vol. 37, no. 41, pp. 5585–5586 . https://doi.org/10.1038/s41388-018-0495-6

Correction to : Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138). / Elias, D.; Vever, H.; Lænkholm, A. V. et al.

In: Oncogene, Vol. 37, No. 41, 10.2018, p. 5585–5586 .

Research output: Contribution to journal › Comment/debate › Research › peer-review

TY - JOUR

T1 - Correction to

T2 - Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)

AU - Elias, D.

AU - Vever, H.

AU - Lænkholm, A. V.

AU - Gjerstorff, M. F.

AU - Yde, C. W.

AU - Lykkesfeldt, A. E.

AU - Ditzel, H. J.

PY - 2018/10

Y1 - 2018/10

N2 - Since the online publication of the above article, the authors have noted errors in subfigures 1c and 3b. Therefore, new images of the original immmunocytochemistry stainings have been obtained for Fig. 1c, and the Western blots for siRNA-mediated FYN knockdown in Fig. 3b were repeated. The amended versions of Figs. 1c and 3b are now provided.

AB - Since the online publication of the above article, the authors have noted errors in subfigures 1c and 3b. Therefore, new images of the original immmunocytochemistry stainings have been obtained for Fig. 1c, and the Western blots for siRNA-mediated FYN knockdown in Fig. 3b were repeated. The amended versions of Figs. 1c and 3b are now provided.

U2 - 10.1038/s41388-018-0495-6

DO - 10.1038/s41388-018-0495-6

M3 - Comment/debate

C2 - 30242243

AN - SCOPUS:85053678231

VL - 37

SP - 5585

EP - 5586

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 41

ER -

Elias D, Vever H, Lænkholm AV, Gjerstorff MF, Yde CW, Lykkesfeldt AE et al. Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138). Oncogene. 2018 Oct;37(41):5585–5586 . doi: 10.1038/s41388-018-0495-6

Correction to: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapy (Oncogene, (2015), 34, 15, (1919-1927), 10.1038/onc.2014.138)

Abstract

Documents & Links

Fingerprint

Related Research Output

Correction: VersicanV1 promotes proliferation and metastasis of hepatocellular carcinoma through the activation of EGFR–PI3K–AKT pathway (Oncogene, (2018), 37, 41, (5585-5586), 10.1038/s41388-018-0495-6)

Cite this